| STATUS |
The combination Co. is most interested in is with cyclosporin. When cyclosporin is used after an organ transplant, the level of drug in the patient has to be titrated, Co. says. That's because of the wide variability of cyclosporin degradation due to the first-pass effect. With a booster, titration still must be done, but the dose needed to reach the required concentration in plasma will be much reduced and more predictable, Co. explains.
Co. has commissioned the contract research organization MDS Pharma Services to formulate a drug development plan for spiro ortho ester boosters coadministered with cyclosporin, Co. says. Preclinical investigation will begin as soon as Co. decides which compounds to advance to pharmaceutical development, Co. adds
|